<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426633</url>
  </required_header>
  <id_info>
    <org_study_id>GISG-02</org_study_id>
    <nct_id>NCT01426633</nct_id>
  </id_info>
  <brief_title>Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas</brief_title>
  <official_title>Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      L-sarcomas represent about one third of all adult soft tissue sarcomas (24 % liposarcomas and
      12 % leiomyosarcomas). Approval for the induction of trabectedin into the treatment
      armamentarium of advanced and/or metastatic soft tissue sarcomas after treatment failure with
      anthracyclines and/or ifosfamide depended mainly on its activity in the L-sarcomas
      (Garcia-Carbonero 2004, Le Cesne 2005, and Demetri 2009). Significant activity has been
      described for the use of gemcitabine and especially the combination of gemcitabine and
      docetaxel mainly in leiomyosarcomas and liposarcomas (Maki 2007). However, the combination of
      gemcitabine and docetaxel is associated with significant toxicity. Pulmonary toxicity and
      refractory peripheral oedema are the most common severe adverse events. The aim of the
      present phase I study will be to examine safety data of this promising treatment combination
      of gemcitabine and trabectedin in L-sarcomas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the maximum tolerated dose (MTD) of the combination of gemcitabine and trabectedin (Yondelis®) in patients with advanced and/or metastatic leiomyosarcoma and liposarcoma.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the recommended phase II dose (RPTD) of the combination of gemcitabine and trabectedin (Yondelis®) in patients with advanced and/or metastatic leiomyosarcoma and liposarcoma.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Leiomyosarcoma</condition>
  <condition>Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Trabectedin</intervention_name>
    <description>Combination therapy of gemcitabine and trabectedin</description>
    <arm_group_label>Gemcitabine + Trabectedin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed L-sarcomas (leiomyosarcoma and liposarcoma)

          -  Measurable disease according to RECIST 1.1

          -  Any treatment line except adjuvant setting: evidence of primary metastatic situation
             or disease progression within the last 6 months (based on RECIST 1.1) in computed
             tomography or magnetic resonance imaging

          -  Any prior treatment possible

          -  Age &gt;= 18 years

          -  WHO PS =&lt; 1

          -  Effective contraception during study medication and up to 3 months from treatment
             discontinuation

          -  Signed informed consent form

        Exclusion Criteria:

          -  Surgical intervention &lt; 4 weeks

          -  Pregnancy or lactation

          -  Known allergic reaction to trabectedin or gemcitabine or one of their components

          -  The following laboratory values:

        Absolute neutrophil count &lt; 1.5 x 103/mm3 Platelets &lt; 100.000/mm3 Hb &lt; 9 g/dL Serum
        creatinine &gt;= 2.5 mg/dl SGOT and/or SGPT and/or alkaline phosphatase and/or CPK &gt; 2.5 x ULN
        Total bilirubin &gt; 1 x ULN except in the case of Gilbert's syndrome

          -  Participation in another study (four weeks before and during the study)

          -  Prior malignancy apart from completely resected basal cell carcinoma of the skin or
             carcinoma in situ of the uterine cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Kasper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Mannheim University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mannheim University Medical Center</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Bernd Kasper</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>L-sarcomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

